AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32816951
Drug: MEDI0562 (0.03,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI0562 (0.03, 0.1, 0.3, 1.0, 3.0, or 10 mg/kg) administered intravenously every 2 weeks.
Trial: 32816955
Drug: Pooled alternative
RxNorm normalized name: HERBS/ALTERNATIVE THERAPIES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled alternative treatment to EFTR
Trial: 32817060
Drug: CDKi as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDKi as first-line treatment
Trial: 32817060
Drug: CDKi as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDKi as second-line treatment
Trial: 32817060
Drug: CDKi as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDKi as third-line treatment and beyond
Trial: 32817060
Drug: CDKi treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDKi treatment
Trial: 32817288
Drug: Rituximab (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1,000 mg, two weeks apart) combined with belimumab (10 mg/kg at week 0, W0+2 days, W2+2 days, W4, W8, and W12)
Trial: 32817593
Drug: H3.3K27M-targeted peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H3.3K27M-targeted peptide vaccine administered with poly-ICLC every 3 weeks for 8 cycles, then every 6 weeks.
Trial: 32817593
Drug: H3.3K27M-targeted peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H3.3K27M-targeted peptide vaccine with observed immunological responses.
Trial: 32817593
Drug: H3.3K27M-targeted peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H3.3K27M-targeted peptide vaccine in patients with below-median baseline levels of myeloid-derived suppressor cells.
Trial: 32817593
Drug: Immediate pretreatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate pretreatment dexamethasone administration.
Trial: 32817978
Drug: High antibody
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High antibody level plasma units
Trial: 32818157
Drug: Single full
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single full dose of penicillin
Trial: 32819400
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 6.8 mL/kg
Trial: 32819972
Drug: Ipilimumab 10
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 10 mg/kg every 3 weeks for four doses combined with radiotherapy (9, 15, 18, and 24 Gy) at week 4.
Trial: 32819972
Drug: Ipilimumab 10
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 10 mg/kg every 12 weeks for maintenance after week 24 for patients with clinical benefit.
Trial: 32820223
Drug: Tissue inhibitor
RxNorm normalized name: Tissue inhibitor of metalloproteinases 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue inhibitor of MMP (TIMP)-1 expression in AT
Trial: 32820223
Drug: Plasminogen activator
RxNorm normalized name: Plasminogen activator
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plasminogen activator inhibitor (PAI)-1 expression in AT
Trial: 32820223
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity measured by glucose clamp technique
Trial: 32820369
Drug: Pretargeted immuno-PET
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretargeted immuno-PET using anti-CEA recombinant bispecific monoclonal antibody (BsMAb) TF2 and gallium-68-labelled IMP-288 peptide
Trial: 32820369
Drug: BsMAb and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BsMAb and peptide injections
Trial: 32820452
Drug: β-glucan, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-glucan, 200 mg/day for 8 weeks
Trial: 32820453
Drug: Integrated Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Chinese and Western medicine (ICM) group receiving CM herbal treatment combined with Western medicine (WM) anti-tumor therapy
Trial: 32820453
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine (CM) group receiving only CM herbal treatment
Trial: 32820453
Drug: WM group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WM group receiving only WM anti-tumor therapy
Trial: 32821164
Drug: Apatinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib monotherapy
Trial: 32821164
Drug: Apatinib combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib combination therapy
Trial: 32821164
Drug: Apatinib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (both monotherapy and combination)
Trial: 32821287
Drug: Clarithromycin triple
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin triple therapy with add-on NAC
Trial: 32821287
Drug: Clarithromycin triple
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin triple therapy alone
Trial: 32821422
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of medication (SAM) during hospitalization
Trial: 32821712
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (4 g/day) plus statin
Trial: 32821737
Drug: New generic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New generic rosuvastatin 10 mg daily for 8 weeks
Trial: 32821737
Drug: Proprietary rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprietary rosuvastatin 10 mg daily for 8 weeks
Trial: 32824065
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein intake (mean 82.2 ± 21.3 g/d)
Trial: 32824392
Drug: Primary tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary tumor resection (PTR) followed by chemotherapy
Trial: 32824392
Drug: Upfront chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upfront chemotherapy alone
Trial: 32829467
Drug: Antiviral and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral and immunomodulator treatment
Trial: 32829481
Drug: Alternative modes
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative modes of exercise therapy (cycling, lower-extremity resistance training, upper-arm ergometry, Nordic walking, combinations of exercise modes)
Trial: 32829481
Drug: Alternative modes
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative modes of exercise therapy
Trial: 32833107
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (NPWT) with FI
Trial: 32833107
Drug: Non-negative pressure
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-negative pressure wound therapy (non-NPWT) with NFI
Trial: 32833717
Drug: Preoperative medications
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative medications
Trial: 32833717
Drug: Home medications
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home medications for comorbidities
Trial: 32833717
Drug: Intraoperative acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative acetaminophen
Trial: 32833717
Drug: Intravenous anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anesthesia induction
Trial: 32838109
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase 50 mg
Trial: 32838109
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase 100 mg
Trial: 32839491
Drug: AsiDNA 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AsiDNA 600 mg
Trial: 32839491
Drug: AsiDNA 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AsiDNA 900 mg
Trial: 32839491
Drug: AsiDNA (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AsiDNA (all doses)
Trial: 32840736
Drug: Anti-CD19 Chimeric
RxNorm normalized name: allogeneic anti-CD19 chimeric antigen receptor (CAR)-T cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CD19 Chimeric Antigen Receptor T Cell (CAR T) Therapy
Trial: 32841335
Drug: Levothyroxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine treatment before conception (BC)
Trial: 32841335
Drug: Levothyroxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine treatment after conception (AC)
Trial: 32841541
Drug: Sorafenib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib plus doxorubicin (sorafenib 400 mg twice daily and doxorubicin 60 mg/m2)
Trial: 32842170
Drug: Basal factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal factor level <0.4 IU/mL
Trial: 32843490
Drug: M4112 (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M4112 (100, 200, 400, 600, and 800 mg two times per day orally)
Trial: 32843493
Drug: CAR-T targeting
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-T targeting carcinoembryonic antigen (CEA) delivered via hepatic artery infusion (HAI) using Pressure-Enabled Drug Delivery (PEDD)
Trial: 32843493
Drug: Interleukin-2 systemically
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interleukin-2 systemically delivered by continuous intravenous infusion
Trial: 32844378
Drug: Sirukumab 100
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 100 mg every 2 weeks plus 6-month prednisone taper
Trial: 32844378
Drug: Sirukumab 50
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 50 mg every 4 weeks plus 6-month prednisone taper
Trial: 32844378
Drug: Placebo every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo every 2 weeks plus 6-month or 12-month prednisone taper
Trial: 32845852
Drug: HEpiTracker app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HEpiTracker app for tracking COVID-19 symptoms, daily body temperature, and health score reporting.
Trial: 36920756
Drug: Closed-loop system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop system of insulin delivery
Trial: 32846062
Drug: Sensor-augmented insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensor-augmented insulin pump (control group)
Trial: 32847933
Drug: LY3022855 (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3022855 (1.25 mg/kg every 2 weeks)
Trial: 32847933
Drug: LY3022855 (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3022855 (1.0 mg/kg on weeks 1, 2, 4, and 5)
Trial: 32847933
Drug: LY3022855 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3022855 (100 mg once weekly)
Trial: 32847933
Drug: LY3022855 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3022855 (100 mg every 2 weeks)
Trial: 32847973
Drug: Sorafenib, Bevacizumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib, Bevacizumab, and Paclitaxel (Paclitaxel 80 mg/m2)
Trial: 32849667
Drug: Live viral
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live viral vaccines (including measles-mumps-rubella - MMR)
Trial: 32849914
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) in combination with bevacizumab/oxaliplatin/fluoropyrimidine regimens (mFOLFOX-6/mOXXEL)
Trial: 32850876
Drug: Oral Psoralen
RxNorm normalized name: Psoralen
DrugBank: Psoralen (DB18665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Psoralen Plus UV-A (PUVA) Photochemotherapy
Trial: 32851490
Drug: Oral water
RxNorm normalized name: Oral Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral water ingestion
Trial: 32856068
Drug: Idelalisib 150
RxNorm normalized name: idelalisib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idelalisib 150 mg twice daily
Trial: 32856153
Drug: FLER analysis
RxNorm normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLER analysis and visualization using indocyanine green (0.2 mg/kg)
Trial: 32857114
Drug: Bimodal Condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimodal Condition (Cochlear Implant + Hearing Aid)
Trial: 32857590
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) therapy, details on dosage and duration not specified.
Trial: 32858582
Drug: MRI-guided focused
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI-guided focused ultrasound (US) treatment
Trial: 34550757
Drug: Poziotinib treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poziotinib treatment
Trial: 32860424
Drug: Benzodiazepines and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepines and Z-drugs (BZD/Z)
Trial: 32863016
Drug: Volume expansion
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume expansion with 250 ml of saline 0.9% over 10 min
Trial: 32863639
Drug: Protocolized sedative
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocolized sedative weaning
Trial: 32864448
Drug: Modified Lempert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Lempert maneuver (ML)
Trial: 32864625
Drug: Alpelisib, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpelisib, a selective inhibitor of PI3Kα
Trial: 32865293
Drug: Hetrombopag 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hetrombopag 2.5 mg/day
Trial: 32865293
Drug: Hetrombopag 5
RxNorm normalized name: eltrombopag 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hetrombopag 5 mg/day
Trial: 32865293
Drug: Hetrombopag 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hetrombopag 7.5 mg/day
Trial: 32866202
Drug: Tablet App
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet App for the Simplified Gestational Age Score (T-SGAS)
Trial: 32867573
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E treatment for 4 weeks
Trial: 32867715
Drug: Nivolumab in
RxNorm normalized name: nivolumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab in combination with FOLFOXIRI/bevacizumab every 2 weeks for 8 cycles followed by maintenance with bevacizumab plus nivolumab every 2 weeks.
Trial: 32867715
Drug: Nivolumab in
RxNorm normalized name: nivolumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab in combination with FOLFOXIRI/bevacizumab
Trial: 32868037
Drug: Edaravone 30
RxNorm normalized name: edaravone 30 MG in 100 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone 30 mg IV infusion over 60 min
Trial: 32868346
Drug: Oral flucloxacillin
RxNorm normalized name: cloxacillin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral flucloxacillin 500 mg-1 g four times a day
Trial: 32870250
Drug: Mavorixafor 400
RxNorm normalized name: Mavorixafor
DrugBank: Mavorixafor (DB05501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavorixafor 400 mg once daily
Trial: 32873270
Drug: Dose-dense TPF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense TPF (ddTPF) chemotherapy with cisplatin and docetaxel 50 mg/m2 on day 1, leucovorin 250 mg/m2 on day 1, followed by 48-h continuous infusion of 2500 mg/m2 of 5-fluorouracil on day 1 and 2, every 2 weeks for 6 cycles followed by radiotherapy.
Trial: 32873343
Drug: Chidamide, decitabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chidamide, decitabine, cytarabine, aclarubicin, and G-CSF (CDCAG)
Trial: 32874573
Drug: Ixazomib (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib (4.0 mg dose)
Trial: 32874839
Drug: Topical atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical atropine 0.125%
Trial: 32875289
Drug: onabotulinumtoxinA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: onabotulinumtoxinA treatment
Trial: 32876349
Drug: Vedolizumab 300
RxNorm normalized name: vedolizumab 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab 300 mg IV every 4 weeks
Trial: 32877254
Drug: Estradiol (E2;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol (E2; 4-µg and 10-µg) softgel vaginal insert
Trial: 32877573
Drug: UA-lowering drugs
RxNorm normalized name: biguanide blood glucose lower drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UA-lowering drugs
Trial: 32878377
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months treatment (defocused communication and behavioural techniques)
Trial: 32878566
Drug: Aspirin therapy
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin therapy (standard- and low-dose, ≥3× per week)
Trial: 32878766
Drug: DKN-01 300
RxNorm normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DKN-01 300 mg combined with gemcitabine (1,000 mg/m2) and cisplatin
Trial: 32878766
Drug: DKN-01 300
RxNorm normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DKN-01 300 mg
Trial: 32878766
Drug: DKN-01 600
RxNorm normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DKN-01 600 mg
Trial: 32879034
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vital sign information with static clinical data
Trial: 32879326
Drug: Crolibulin (13-24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crolibulin (13-24 mg/m2)
Trial: 32881280
Drug: ctDNA analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ctDNA analysis with therapy matched to ctDNA alterations (N=33 patients)
Trial: 32881886
Drug: L-Arginine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Arginine (100 mg/kg single dose)
Trial: 32881886
Drug: L-Arginine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Arginine (100 mg/kg three times daily po X 6 weeks)
Trial: 32882399
Drug: Beta-blocker intake
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker intake before exposure to loud noise (∼100 dB)
Trial: 32882399
Drug: Beta-blocker intake
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker intake before simulated diving (face immersion in cold water)
Trial: 32882958
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health activities incorporated into pediatric well-child visits
Trial: 32882958
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard pediatric well-child visits without oral health activities)
Trial: 32883871
Drug: CD19-28ζ CAR
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-28ζ CAR T-cell therapy
Trial: 32884231
Drug: Topical Latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical Latanoprost 0.005%
Trial: 32884231
Drug: Topical Timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical Timolol Maleate 0.5%
Trial: 32884828
Drug: AbobotulinumtoxinA (aboBoNT-A)
RxNorm normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: AbobotulinumtoxinA (aboBoNT-A) using 2-mL dilution (500 U/2-mL)